DJIA 17,598.20 0.00 0.00%
NASDAQ 5,115.38 0.00 0.00%
S&P 500 2,098.04 0.00 0.00%
market minute promo

Vertex Pharmaceuticals (NASDAQ: VRTX)



company name or ticker
Company Photos
(Click to zoom)

3 Potential Huge Takeover Targets in Biotech

Vertex Posts Wider Y/Y Loss but Raises Kalydeco Outlook - Analyst Blog

3 Drugs Stocks Pushing Industry Growth

Vertex Pharmaceuticals (VRTX) Earnings Report: Q2 2015 Conference Call Transcript

Vertex Pharmaceuticals (VRTX) Jeffrey M. Leiden on Q2 2015 Results - Earnings Call Transcript

Vertex Pharmaceuticals Rolls Along

Solid quarter, but Orkambi sales in future quarters will dictate the biotech’s fate.

Trade-Ideas: Vertex Pharmaceuticals (VRTX) Is Today's Post-Market Leader Stock

Biotech Stock Roundup: Biogen Down on Tecfidera Issues, Regeneron's Praluent Gets FDA Nod - Analyst

Biotech Stock Roundup: Biogen Down on Tecfidera Issues, Regeneron's Praluent Gets FDA Nod - Analyst Blog

Earnings Reaction History: Vertex Pharmaceuticals Incorporated, 66.7% Follow-Through Indicator, 3.8%

Earnings Reaction History: Vertex Pharmaceuticals Incorporated, 66.7% Follow-Through Indicator, 3.8% Sensitive

The Secret to Vertex Pharmaceuticals' Success

Originally set out to treat the hepatitis C market, Vertex has successfully pivoted its focus to the cystic fibrosis market instead, where it looks poised for strong growth.
See More Articles...